{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-057691","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.421876+00:00","generated_at":"2026-06-02T18:50:44.453688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge","bullets":["Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.","Net loss $141.4M ($2.35/share) vs $52.2M ($0.92/share) prior year; R&D spend $128.7M incl $92.4M IPR&D for LB54640.","Cash $201M at March 31; closed $150M preferred stock financing April 15 extending runway into 2026.","On track to submit sNDA for IMCIVREE in pediatric patients 2 to <6 years old in Q2 2024.","Phase 3 hypothalamic obesity trial top-line data expected H1 2025; Japanese cohort dosing starts Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-057691","json":"https://secwatch.observer/filing/0001104659-24-057691.json","markdown":"https://secwatch.observer/filing/0001104659-24-057691.md","text":"https://secwatch.observer/filing/0001104659-24-057691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/0001104659-24-057691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/tm2413330d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:50:44.453688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca6acc2bccbfb3f4bc10d5c66968fa47beb507b8","claim":"RHYTHM PHARMACEUTICALS, INC. reported for the quarter ended March 31, 2024 results: revenue $26.0 million.","evidence_excerpt":"Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924057691/0001104659-24-057691-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2024"},{"label":"Revenue","value":"$26.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}